Principal Financial Group’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$241K Buy
+7,009
New +$212K ﹤0.01% 2069
2024
Q3
– Sell
-10,400
Closed -$244K – 2249
2024
Q2
$244K Sell
10,400
-8,018
-44% -$197K ﹤0.01% 2101
2024
Q1
$609K Buy
18,418
+789
+4% +$24.6K ﹤0.01% 1945
2023
Q4
$480K Buy
17,629
+284
+2% +$7.05K ﹤0.01% 1961
2023
Q3
$417K Buy
17,345
+19
+0.1% +$509 ﹤0.01% 1988
2023
Q2
$553K Buy
17,326
+421
+2% +$13.7K ﹤0.01% 1930
2023
Q1
$518K Sell
16,905
-1,101
-6% -$43.5K ﹤0.01% 1960
2022
Q4
$704K Buy
18,006
+895
+5% +$40.1K ﹤0.01% 1907
2022
Q3
$816K Sell
17,111
-462
-3% -$26.4K ﹤0.01% 1868
2022
Q2
$681K Sell
17,573
-3,795
-18% -$151K ﹤0.01% 1989
2022
Q1
$1.23M Buy
21,368
+351
+2% +$23K ﹤0.01% 1940
2021
Q4
$1.68M Sell
21,017
-5,632
-21% -$482K ﹤0.01% 1884
2021
Q3
$2.32M Buy
26,649
+5,757
+28% +$578K ﹤0.01% 1844
2021
Q2
$2.69M Buy
20,892
+674
+3% +$53.7K ﹤0.01% 1846
2021
Q1
$1.62M Sell
20,218
-564
-3% -$53.7K ﹤0.01% 1897
2020
Q4
$1.7M Buy
+20,782
New +$1.02M ﹤0.01% 1830

Other funds holding BEAM

Principal Financial Group's BEAM Position: Q2 2026 in Review

Principal Financial Group opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 7,009 shares worth $241K. The stake represents ﹤0.01% of the portfolio and ranks #2069 among its holdings. This is a return to the name: Principal Financial Group previously reported a position in BEAM as recently as Q2 2024.

Principal Financial Group first reported a position in BEAM in Q4 2020 and has held it in 16 quarters since. The position peaked at $2.69M in Q2 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Principal Financial Group held 7,009 shares of Beam Therapeutics worth $241K as of Q2 2026.
  • Beam Therapeutics was a new Principal Financial Group position in Q2 2026.
  • Beam Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #2069 holding.
  • Principal Financial Group first reported a position in Beam Therapeutics in Q4 2020 and has held it in 16 quarters since.
  • Principal Financial Group's Beam Therapeutics position peaked at $2.69M in Q2 2021.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.